Chemistry: molecular biology and microbiology – Differentiated tissue or organ other than blood – per se – or... – Including freezing; composition therefor
Reexamination Certificate
2008-04-08
2008-04-08
Naff, David M. (Department: 1657)
Chemistry: molecular biology and microbiology
Differentiated tissue or organ other than blood, per se, or...
Including freezing; composition therefor
C424S423000, C424S093700, C435S177000, C435S395000
Reexamination Certificate
active
07354702
ABSTRACT:
A method of forming and preserving a bioremodelable, biopolymer scaffold material by subjecting animal tissue, particularly fetal or neo-natal tissue, to chemical and mechanical processing. The process includes, but is not limited to, harvesting the tissue, optionally extracting growth and differentiation factors from the tissue, inactivating infective agents of the tissue, mechanically expressing undesirable components from the tissue, delipidizing the tissue, washing the tissue, optionally drying the tissue, optionally cross-linking the tissue not necessarily in the order described. The resulting product, EBM, is characterized by its microbial, fungal, viral and prion inactivated state. EBM is strong, bioremodelable, drapable and does not undergo calcification. EBM supplants previous inventions because of its unique method of preparation and broad applicability in tissue reengineering.
REFERENCES:
patent: 4801299 (1989-01-01), Brendel et al.
patent: 4971954 (1990-11-01), Brodsky et al.
patent: 5336616 (1994-08-01), Livesey et al.
patent: 5624463 (1997-04-01), Stone et al.
patent: 5756678 (1998-05-01), Shenoy et al.
patent: 5876742 (1999-03-01), Cochrum et al.
patent: 5916265 (1999-06-01), Hu
patent: 5997895 (1999-12-01), Naratam et al.
patent: 6179872 (2001-01-01), Bell et al.
patent: 6379615 (2002-04-01), Ogle
patent: 6468313 (2002-10-01), Claeson et al.
patent: 6696074 (2004-02-01), Dai et al.
International Search Report for PCT/US02/15620 (Jun. 17, 2003).
Darbord, “Inactivation of Prions in Daily Medical Practice,”Biomed&Pharmacother34:8 (1999).
Diringer et al., Infectivity of Unconventional Viruses in Dura Mater,The Lancet, 1:439-440 (1989).
U.S. Dept. Health and Human Services, “Guide for 510(K) Review of Processed Human Dura Mater,” (1990) 2 FDA.
U.S. Dept. Health and Human Services, “Guidance for the Preparation of a Premarket Notification Application for Dura Mater,” (1999) 6 FDA.
Bell Eugene
Dai Jianwu
Russakovsky Vladimir
Fish & Richardson P.C.
Naff David M.
TEI Biosciences, Inc.
LandOfFree
Processing tissue to produce a biopolymer scaffold for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Processing tissue to produce a biopolymer scaffold for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Processing tissue to produce a biopolymer scaffold for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2773709